{"prompt": "['2016N277425_01', 'CONFIDENTIAL', '2018N377698_00', '201749', 'outweigh the risk in conditions such as:', 'Myocardial infarction or unstable angina in the last 6 months', 'Unstable or life threatening cardiac arrhythmia requiring intervention in the last 3', 'months', 'NYHA Class IV heart failure', '6.', '12 Lead ECG: The Investigator will determine the clinical significance of each', \"abnormal ECG finding in relation to the subject's medical history and exclude\", 'subjects who would be at undue risk by participating in the trial. Subjects with the', 'following abnormalities are excluded from participation in the study:', 'Atrial fibrillation with rapid ventricular rate > 120 bpm', 'Sustained or non-sustained ventricular tachycardia', 'Second degree heart block Mobitz type II or third degree heart block (unless', 'pacemaker or defibrillator had been inserted)', '7.', 'Antimuscarinic effects: Subjects with medical conditions such as narrow-angle', 'glaucoma, urinary retention, prostatic hypertrophy, or bladder neck obstruction', 'should be excluded unless, in the opinion of the study physician, the benefit', 'outweighs the risk.', '8.', 'Other disease abnormalities: Any subject who is considered unlikely to survive', 'the duration of the study period or has any rapidly progressing disease or', 'immediate life-threatening illness (e.g. cancer). In addition, any subject who has', 'any other condition (e.g. neurological condition) that is likely to affect respiratory', 'function should not be included in the study.', '9.', 'Hospitalization: Hospitalization for COPD or pneumonia within 12 weeks prior', 'to Visit 1. Pneumonia and/or moderate or severe COPD exacerbation that has', 'not resolved at least 14 days prior to Screening V1 and at least 30 days following', 'the last dose of oral/systemic corticosteroids (if applicable).', '10.', 'Inhaled corticosteroids (ICS): Had received ICS or ICS/LABA for the treatment', 'of COPD in the 6 weeks prior to Screening Visitl', '11.', 'Exacerbation: Had >1 moderate exacerbation in the 12 months prior Screening', 'Visitl, or one severe exacerbation requiring hospitalisation in the 12 months prior', 'Screening Visit 1.', '12.', 'Other respiratory tract infections that have not resolved at least 7 days prior to', 'Screening V1.', '13.', 'Lung Resection: Subjects with lung volume reduction surgery (including', 'procedures such as endobronchial valves) within the 12 months prior to Screening', 'V1.', '14.', 'Oxygen: Use of long-term oxygen therapy (LTOT) described as resting oxygen', 'therapy >3L/min at screening required to maintain adequate oxygenation (e.g.', 'SaO2 >90%). (Oxygen use <3L/min flow is not exclusionary, and patients may', 'adjust oxygen levels up or down as needed during the study.)', '28']['2016N277425_01', 'CONFIDENTIAL', '2018N377698_00', '201749', 'CONCOMITANT MEDICATIONS', '1. Medications prior to Screening: Use of the following medications according to', 'the following defined time intervals prior to Screening (Visit 1):', 'Medication', 'No use within the', 'following time intervals', 'prior to Screening', 'Inhaled corticosteroids (ICS)', '6 weeks', 'Depot corticosteroids', '12 weeks', 'Systemic, oral or parenteral corticosteroidsa', '6 weeks', 'Antibiotics (for lower respiratory tract infection)', '6 weeks', 'Phosphodiesterase 4 (PDE4) Inhibitor (e.g roflumilast)', '14 days', 'LABA/Inhaled Corticosteroid (ICS) combination products', '6 weeks', 'Theophyllines', '48 hours', 'Oral beta2-agonists', 'Long-acting', '48 hours', 'Short-acting', '12 hours', 'Inhaled short acting beta2-agonistsb', '4 hours', 'Inhaled short-acting anticholinergics', '4 hours', 'Inhaled short-acting anticholinergic/short-acting beta2-agonist', '4 hours', 'combination products', 'Any other investigational medication', '30 days or within 5 drug', 'half-lives (whichever is', 'longer)', 'a- Localized corticosteroid injections (e.g., intra-articular and epidural) are permitted.', 'b- Use of study provided albuterol/salbutamol is permitted during the study, except in the 4-hour period prior to', 'spirometry testing', '2. Medication prior to spirometry: Unable to withhold albuterol/salbutamol for', 'the 4 hour period required prior to spirometry testing at each study visit.', '3. Maintenance use of short-acting bronchodilators: Regular use (prescribed for', 'daily/ regular use, not for as-needed use) of short-acting bronchodilators (e.g.', 'lbuterol/salbutamol)', 'RELEVANT HABITS', '1. Drug or alcohol abuse: A known or suspected history of alcohol or drug abuse', 'within 2 years prior to Screening Visit 1 that in the opinion of the investigator would', 'prevent the subject from completing the study procedures.', 'CONTRAINDICATIONS', '1. Any history of allergy or hypersensitivity to any anticholinergic/muscarinic', 'receptor antagonist, sympathomimetic, lactose/milk protein or magnesium stearate.', '29']\n\n###\n\n", "completion": "END"}